Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

Månsson, Emma; Flordal, Emma; Liliemark, Jan; Spasokoukotskaja, Tatiana; Elford, Howard; Lagercrantz, Svetlana; Eriksson, Staffan; Albertioni, Freidoun

Månsson, Emma; Flordal, Emma; Liliemark, Jan; Spasokoukotskaja, Tatiana; Elford, Howard; Lagercrantz, Svetlana; Eriksson, Staffan; Albertioni, Freidoun.

Affiliation

Månsson E; Department of Medicine, Division of Clinical Pharmacology, Karolinska Hospital, SE-17176 Stockholm, Sweden.

Biochem Pharmacol ; 65(2): 237-47, 2003 Jan 15.

Article in En | MEDLINE | ID: mdl-12504799

Subject(s)

Antineoplastic Agents/pharmacology; Arabinonucleosides/pharmacology; Cladribine/pharmacology; Deoxycytidine Kinase/metabolism; Ribonucleotide Reductases/metabolism; Vidarabine/analogs & derivatives; Vidarabine/pharmacology; Adenine Nucleotides; Cell Line; Clofarabine; Cytogenetics; Down-Regulation/drug effects; Drug Resistance, Neoplasm; Enzyme Activation/drug effects; Humans; Leukemia/pathology; Phenotype; Phosphorylation; Ribonucleotide Reductases/antagonists & inhibitors

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Ribonucleotide Reductases / Vidarabine / Arabinonucleosides / Cladribine / Deoxycytidine Kinase / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Biochem Pharmacol Year: 2003 Type: Article Affiliation country: Sweden

Search on Google

Add to My VHL

XML

PubMed Links